Drug interactions
Lorlatinib + Telotristat ethyl
Severity: Moderate
Lorlatinib and Telotristat ethyl: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Telotristat may reduce CYP3A4 substrate exposure and could lower lorlatinib concentrations, risking reduced efficacy. Lorlatinib combined with CYP3A inducers has also been associated with hepatotoxicity.
What this interaction means in plain words
Lorlatinib and Telotristat ethyl can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Telotristat induces CYP3A4, increasing lorlatinib metabolism.
What to do
Avoid combining where possible; if unavoidable, monitor ALT, AST and bilirubin and assess lorlatinib efficacy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Telotristat ethyl, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Telotristat ethyl?
MediHelp rates the interaction as moderate. Lorlatinib and Telotristat ethyl can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Telotristat may reduce CYP3A4 substrate exposure and could lower lorlatinib concentrations, risking reduced efficacy. Lorlatinib combined with CYP3A inducers has also been associated with hepatotoxicity.
How serious is the interaction between Lorlatinib and Telotristat ethyl?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible; if unavoidable, monitor ALT, AST and bilirubin and assess lorlatinib efficacy.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
